| abstract |
The present invention relates to substituted aza- and diaza-cyclic compounds of formula I wherein Ar.sup.1.n. represents a group of formula A1 or a 5- or 6-membered optionally substituted heteroaromatic ring optionally containing up to three heteroatoms selected independently from oxygen, nitrogen and sulfur; is H or optionally substituted C 1-7 alkyl-C 1-6 alkyl; R.sup.2.n. is H, optionally substituted with C.sub.1. or CO.sub.2. A is C.sub.3., C.sub.15.alpha.-alkylene or C.sub.4.times.-alkylene or a group formed from C.sub. 3.n.-C.alpha.-alkylene, interrupted by at least one Z group, or bound by at least one Z group to the Ar group, wherein Z is selected from the group consisting of oxygen and sulfur. , NR.sup.1, double and triple bonds; B represents groups of formula VB; Ar.sup.2.n. is optionally substituted phenyl, pyridyl, pyrimidinyl or triazinyl or Ar.sup.2. it may be fused to a 5- or 6-membered carbocyclic optionally substituted aromatic or non-aromatic ring; and salts thereof with physiologically acceptable acids, pharmaceutical compositions containing them, and their use in the treatment of disorders related to dopamine receptor antagonists or agonists, e.g., central nervous system disorders. |